Puma Biotechnology traded at $4.24 this Friday January 27th, decreasing $0.18 or 4.07 percent since the previous trading session. Looking back, over the last four weeks, Puma Biotechnology lost 5.74 percent. Over the last 12 months, its price rose by 85.96 percent. Looking ahead, we forecast Puma Biotechnology to be priced at 4.24 by the end of this quarter and at 3.83 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.24
Daily Change
-4.07%
Yearly
85.96%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,134.00 -42.00 -1.01% 24.26%
Daiichi Sankyo 4,335.00 -42.00 -0.96% 67.80%
Agios Pharmaceuticals 30.75 0.03 0.10% 2.30%
Alnylam Pharmaceuticals 231.37 -0.22 -0.10% 75.16%
Amgen 253.65 -1.23 -0.48% 10.70%
Biogen 290.08 -1.84 -0.63% 28.80%
Bluebird Bio 6.28 0.05 0.80% -16.60%
BioMarin Pharmaceutical 117.27 0.29 0.25% 36.11%
Clovis Oncology 0.11 -0.001 -0.90% -94.30%
Esperion Therapeutics 6.68 0.03 0.45% 64.13%
Exelixis 17.47 -0.24 -1.36% -1.69%
Gilead Sciences 83.70 0.11 0.13% 21.55%
Glaxosmithkline 35.30 -0.04 -0.11% -21.99%
Intercept Pharmaceuticals 18.40 0.03 0.16% 18.40%
Incyte Corp 85.70 -0.31 -0.36% 15.45%
MacroGenics 5.74 -0.18 -3.04% -51.64%
Moderna Inc 189.35 -3.89 -2.01% 18.74%
Mirati Therapeutics 53.09 2.03 3.98% -53.00%
Novartis 82.58 -0.10 -0.12% 4.04%
Puma Biotechnology 4.24 -0.18 -4.07% 85.96%
Pfizer 43.79 -0.46 -1.04% -19.40%
PTC Therapeutics 46.25 0.26 0.57% 18.50%
Ultragenyx Pharmaceutical 43.72 -0.42 -0.95% -33.76%
Regeneron Pharmaceuticals 742.97 0.53 0.07% 18.89%
Roche Holding 289.35 0.35 0.12% -18.60%
Seattle Genetics 140.67 0.98 0.70% 10.23%
Sangamo BioSciences 3.58 0.13 3.77% -37.30%
Spectrum Pharmaceuticals 0.57 -0.02 -2.70% -18.01%
Sarepta Therapeutics 122.89 -1.58 -1.27% 76.34%
TG Therapeutics 14.63 0.48 3.39% 50.36%
Vanda Pharmaceuticals 7.65 -0.04 -0.52% -48.10%
Vertex Pharmaceuticals 321.77 0.43 0.13% 32.40%

Indexes Price Day Year
US2000 1911 8.39 0.44% -2.90%

Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.